Zimmer Biomet Holdings, Inc. $ZBH Shares Sold by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC decreased its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 31.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 32,727 shares of the medical equipment provider’s stock after selling 15,033 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Zimmer Biomet were worth $3,217,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of ZBH. Dodge & Cox increased its holdings in shares of Zimmer Biomet by 12.9% in the second quarter. Dodge & Cox now owns 22,097,463 shares of the medical equipment provider’s stock valued at $2,015,510,000 after purchasing an additional 2,533,009 shares during the last quarter. Norges Bank acquired a new position in Zimmer Biomet during the second quarter worth $225,867,000. AQR Capital Management LLC grew its holdings in Zimmer Biomet by 276.6% in the 2nd quarter. AQR Capital Management LLC now owns 1,300,593 shares of the medical equipment provider’s stock valued at $118,627,000 after buying an additional 955,284 shares in the last quarter. Capital International Investors increased its stake in shares of Zimmer Biomet by 11.5% in the 3rd quarter. Capital International Investors now owns 7,550,754 shares of the medical equipment provider’s stock worth $743,749,000 after acquiring an additional 778,467 shares during the last quarter. Finally, Invesco Ltd. raised its holdings in shares of Zimmer Biomet by 11.5% during the 2nd quarter. Invesco Ltd. now owns 4,606,591 shares of the medical equipment provider’s stock worth $420,167,000 after acquiring an additional 475,921 shares during the period. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Trading Up 1.9%

Shares of ZBH stock opened at $90.26 on Wednesday. Zimmer Biomet Holdings, Inc. has a 1-year low of $84.59 and a 1-year high of $114.44. The firm has a market cap of $17.66 billion, a PE ratio of 25.50, a price-to-earnings-growth ratio of 1.81 and a beta of 0.58. The company has a 50-day moving average of $92.09 and a two-hundred day moving average of $93.81. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.98 and a quick ratio of 1.10.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $2.42 EPS for the quarter, topping the consensus estimate of $2.38 by $0.04. The firm had revenue of $2.24 billion for the quarter, compared to analyst estimates of $2.22 billion. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The business’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same period in the prior year, the business posted $2.31 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. On average, analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 1.1%. The ex-dividend date is Tuesday, March 31st. Zimmer Biomet’s dividend payout ratio (DPR) is currently 27.12%.

Analyst Upgrades and Downgrades

ZBH has been the topic of several recent research reports. Wells Fargo & Company upped their price objective on shares of Zimmer Biomet from $93.00 to $98.00 and gave the company an “equal weight” rating in a report on Wednesday, February 11th. Barclays reduced their target price on shares of Zimmer Biomet from $104.00 to $100.00 and set an “underweight” rating on the stock in a research note on Thursday, February 12th. William Blair initiated coverage on shares of Zimmer Biomet in a research note on Friday, February 20th. They issued a “market perform” rating for the company. Evercore raised shares of Zimmer Biomet from an “in-line” rating to an “outperform” rating and lifted their price target for the company from $94.00 to $120.00 in a research report on Monday, January 5th. Finally, Wall Street Zen cut Zimmer Biomet from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, ten have issued a Hold rating and four have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $106.20.

Insider Buying and Selling at Zimmer Biomet

In related news, SVP Lori Winkler sold 2,650 shares of the business’s stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $94.66, for a total value of $250,849.00. Following the sale, the senior vice president owned 10,224 shares in the company, valued at approximately $967,803.84. The trade was a 20.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.70% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.